GMED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Globus Medical Inc (GMED) is a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's robust financial performance, consistent analyst upgrades, and strong technical indicators make it a solid investment opportunity.
The technical indicators for GMED are bullish. The MACD histogram is positive and expanding, indicating upward momentum. The RSI is at 79.554, which is in the neutral zone but approaching overbought levels. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its resistance level of R1: 96.294, with potential to test R2: 99.08.
Exceptional Q4 2025 financial performance: Revenue increased by 25.73% YoY, net income surged by 430.44%, and EPS grew by 442.11%.
Analysts consistently raised price targets, with the highest target at $123, citing strong growth in the U.S. spine business and margin improvements.
News sentiment is overwhelmingly positive, with Q4 results exceeding expectations and highlighting significant growth in key business segments.
RSI is approaching overbought levels, which could indicate limited short-term upside.
Lack of significant hedge fund or insider trading activity, which may suggest neutral sentiment from institutional investors.
Globus Medical reported outstanding financial results for Q4 2025. Revenue grew to $826.42 million, up 25.73% YoY. Net income increased to $140.59 million, up 430.44% YoY, and EPS rose to $1.03, up 442.11% YoY. Gross margin improved to 64.85%, reflecting a 17.12% YoY increase.
Analysts are highly bullish on GMED, with multiple firms raising price targets recently. The highest price target is $123, and the lowest is $104, all indicating upside potential from the current price of $97.03. Analysts highlight strong growth in the U.S. spine business, margin improvements, and impressive Q4 results as key drivers for their positive outlook.
